$PNNT

PennantPark Investment Corporation Announces Monthly Distribution of $0.08 per Share

PennantPark Investment Corporation (NYSE: PNNT) announced a July 2026 monthly distribution of $0.08 per share, made up of a $0.04 base dividend and $0.04 supplemental dividend. It will be paid Aug. 3, 2026 to holders of record July 15, 2026, expected from taxable net investment income, with tax details reported later on Form 1099 and SEC filings.

Original reporting
Published Jul 2, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PennantPark Investment Corporation Announces Monthly Distribution of $0.08 per Share — source image
Decision brief

The 30-second read

$PNNTNeutralLow
01

Why it matters

The company declared its July 2026 monthly distribution ($0.04 base + $0.04 supplemental), expected from taxable net investment income, with specific record and payment dates.

02

Market read

Primarily relevant for income/BDC positioning around the July 15 record date and Aug. 3 payment date; limited fundamental signal beyond payout declaration.

03

What to watch

Traders may focus more on the implied coverage (taxable net investment income) and any upcoming NAV/earnings release rather than the declared cash amount alone.

Relevance 5/10Novelty 5/10Timing: payable Aug. 3; stockholders of record July 15

Background

PennantPark Investment Corporation is a business development company (BDC) investing in U.S. middle-market private companies, typically funding returns via interest/dividends.

Company-level read

Ticker impact

$PNNTNeutralMedium confidence
Context

PennantPark Investment Corporation announced a July 2026 monthly distribution of $0.08/share, payable Aug. 3 to holders of record July 15.

Expected impact

Likely modest, mostly mechanical reaction around ex-date/record-date positioning; no fundamental guidance change indicated.

Evidence & confidence

The release provides a concrete payout amount and calendar dates, but does not include earnings, NAV, or portfolio-credit updates that would materially reset fundamentals.

Market effects

Adds another data point on BDC-style monthly distribution cadence, but without sector-wide policy or rate sensitivity details.

Minimal; US-listed BDC income flow only.

Low; company-specific distribution announcement.

Counterpoint

The distribution amount may be largely expected for PNNT; without NAV/earnings context, the market may discount it quickly.

Key entities

  • PennantPark Investment Corporation

    BDC declaring monthly distribution of $0.08/share for July 2026.

  • Form 1099

    Tax reporting to stockholders after calendar year end.

  • Securities and Exchange Commission

    Company periodic reports will include distribution tax characteristics.

Related articles

$PNNTMed

PennantPark Investment Corporation Q3 2026 Earnings Call Summary

PennantPark Investment Corp (PNNT) reported Q3 2026 core net investment income of $0.14 per share, above its base dividend. NAV per share fell 2.5% due to supplemental dividend distributions tied to undistributed taxable income. Management cited a 14x gain on a $1.1m defense tech investment, expects JV portfolio growth to about $1.5b, and said JV refinancings add about $0.02/share annually.

$PNNTMed

PennantPark Investment Corporation Announces Financial Results for the Third Quarter Ended June 30, 2026

PENNANTPARK INVESTMENT CORP (PNNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 PennantPark Investment Corporation Announces Financial Results for the Third Quarter Ended June 30, 2026 MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (NYSE: PNNT) (the "Company") announced today financial results for the third quarter e

$ZYMEMedAI 8/10

Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal

Zymeworks (ZYME) gained attention due to Phase 1 trial data for ZW191 in ovarian cancer and a licensing deal with Roche for ZW209. The stock has seen significant returns: 19.8% in 1 month, 28.2% in 3 months, 65.9% in 1 year, and 4x in 3 years. Analysts debate its valuation, with some seeing it as 27% undervalued at a fair value of $41.50, while others note its high P/B ratio of 26.6x compared to peers.

$NICEMed

NICE cuts 500 jobs as AI reshapes customer-service business

NICE, a customer-service software company, is cutting 5% of its workforce (500 jobs) to adapt to AI-driven changes. It plans to sell its Actimize business, invest in AI, and acquire a German AI startup for $1B. NICE's stock has declined, and revenue is projected to exceed $3B, but earnings may face pressure.

$DORMMed

Dorman Products Eyes Growth in Electronics, Specialty Vehicles and Aftermarket Exclusives

Dorman Products (DORM) sees growth in electronics, specialty vehicles, and aftermarket exclusives. The company expects a large repair-opportunity funnel in North America, driven by high-dollar vehicle failures. Dorman plans to expand in heavy-duty vehicles and consolidate the fragmented specialty vehicle market. CFO Charles Rayfield anticipates a 40% gross margin by Q4, with capital allocation focused on debt maintenance, product development, M&A, and share repurchases.

High

GE Vernova T&D India Gets Power Grid Letter of Award

GE Vernova T&D India (BSE: 522275; NSE: GEVT&D) received a Letter of Award from Power Grid Corporation for a 6,000 MW HVDC transmission project. The project involves a ±800 kV terminal station with two 3,000 MW units. The stock was trading at ₹3,978.60, down 1.76% on November 4, 2026. The contract value was not disclosed.